Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT00517530
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT00518011
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Phase 2
Terminated
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT00517699
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00504777
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: PlaceboDrug: RG3421 120mgDrug: RG3421 20mg
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT00504270
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 246
- Registration Number
- NCT00502996
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 193
- Registration Number
- NCT00502840
- Locations
- 🇩🇪
Rheumapraxis - Dres. Edmund Edelmann, Gerhard Straeßner und Hans Bloching, Bad Aibling, Germany
🇩🇪Campus Charité Mitte Charité Centrum 12. Med.Klinik Abt.Rheumatologie u.Klin.Immunologie, Berlin, Germany
🇩🇪Praxis Dr. Silke Zinke, Berlin, Germany
A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 289
- Registration Number
- NCT00502710
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
Phase 2
Completed
- Conditions
- Pain; Bone Neoplasms; Neoplasm Metastasis
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT00502736
A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00502671
© Copyright 2025. All Rights Reserved by MedPath